Cambridge Epigenetix

company

About

Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
$30M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical
Founded date
Jan 1, 2012
Number Of Employee
51 - 100
Operating Status
Active

Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw.

CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health.

Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease.

A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$139M
Cambridge Epigenetix has raised a total of $139M in funding over 2 rounds. Their latest funding was raised on Nov 2, 2021 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 2, 2021 Series D $88M 1 Detail
Sep 3, 2018 Series C $30M 1 Detail
Mar 14, 2016 Series B $21M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Cambridge Epigenetix is funded by 1 investors. Sequoia Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Sequoia Capital Series D